By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
See as Your #1: These Low-Sugar Food sources You Ought to Attempt - 2Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- 3'No Kings' protests recap: More than 8 million turned out across all 50 states, organizers say
- 4Jenny & Dave Marrs Mourn Loss of Former ‘Fixer to Fabulous: Italiano’ Guest
- 5The Most Encouraging New companies to Look Out For
- Understanding Various Sorts of Financial balances: An Extensive Outline
- The cave was pitch black – so to create this magical underwater shot, the photographer had to use all his camera expertise...
- Employers and staff feel effect of fuel price rise
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- 20-year-old who threatened German train attack remanded in custody
- First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- The Best Internet Mastering Stages for Expertise Improvement
- A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- Iran begins cloud seeding to induce rain amid historic drought
